title: [Autologous peripheral blood CD34+ stem cells transplanted into 100 patients with advanced cirrhosis].
abstract: OBJECTIVE
  To investigate whether transplantation of autologous peripheral blood CD34+ stem cells is a viable approach for treating patients with advanced cirrhosis,which is currently hindered by a shortage in liver donors.
  
  
  METHODS
  A total of 100 patients with advanced cirrhosis and who had failed to respond to conservative therapy were recruited for transplantation of autologous peripheral blood CD34+ stem cells.The success of transplantation was investigated 6-and 12-months later by measuring markers of liver biosynthesis function (coagulation,albumin level,indocyanine green clearance,Child-Pugh score) and assessing pathological changes (Knodell score) and morphologic changes in the liver tissue.Complications were also recorded during follow-up.
  
  
  RESULTS
  The 1-year cumulative survival rate was 100%. Fifty-two patients with massive ascites showed gradual reduction and disappearance of the ascites.Four patients experienced upper gastrointestinal bleeding and three patients developed with hepatic encephalopathy (I-II degree) at 3 months post-transplantation.All patients showed significantly improved liver biosynthesis function,liver elasticity and Knodell score after transplantation (P less than 0.05).
  
  
  CONCLUSIONS
  Autologous peripheral blood CD34+ stem cell transplantation is a safe and effective treatment for advanced cirrhosis,and has high cost-benefit since it improves liver function,liver histology,and quality of life.
authors.affiliation: School of Medicine, UESTC and Sichuan Provincial People's Hospital, Chengdu 610072, China.
authors.forename: Yutong
authors.initials: Y
authors.lastname: Yao
authors.forename: Lanyun
authors.initials: L
authors.lastname: Luo
authors.forename: Hua
authors.initials: H
authors.lastname: Xue
authors.forename: Le
authors.initials: L
authors.lastname: Luo
authors.forename: Haibo
authors.initials: H
authors.lastname: Zou
authors.forename: Guan
authors.initials: G
authors.lastname: Wang
authors.forename: Zhiming
authors.initials: Z
authors.lastname: An
authors.forename: Ming
authors.initials: M
authors.lastname: Zhong
authors.forename: Xiaobing
authors.initials: X
authors.lastname: Huang
authors.forename: Yifan
authors.initials: Y
authors.lastname: Zhu
authors.forename: Lingling
authors.initials: L
authors.lastname: Wei
authors.forename: Maozhu
authors.initials: M
authors.lastname: Yang
authors.forename: Tian
authors.initials: T
authors.lastname: Zhang
authors.forename: Ping
authors.initials: P
authors.lastname: Xie
authors.forename: Gang
authors.initials: G
authors.lastname: Xu
authors.forename: Shaoping
authors.initials: S
authors.lastname: Deng
authors.forename: Xiaolun
authors.initials: X
authors.lastname: Huang
mesh_terms: D001201:Ascites; D006801:Humans; D008103:Liver Cirrhosis / Q000628:therapy*; D011788:Quality of Life; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous; D016896:Treatment Outcome